13 results about "Nuclear transport" patented technology

The invention generally relates to nuclear transport modulators, e.g., CRM1 inhibitors, and more particularly to a compound represented by structural formula I:or a pharmaceutically acceptable salt thereof, wherein the values and alternative values for the variables are as defined and described herein. The invention also includes the synthesis and use of a compound of structural formula I, or a pharmaceutically acceptable salt or composition thereof, e.g., in the treatment, modulation and / or prevention of physiological conditions associated with CRM1 activity.

The present application relates to SLC25A10 leading to drug resistance of liver cancer cells, specifically, liver cancer cells are in a hypoxic environment, and hypoxia enhances the expression of SLC25A10 and triggers the splicing variation of SLC25A10 from isomer 1 to isomer 3. Isomer 3 of SLC25A10 enters the nucleus by combining with nuclear transport protein IPO7, and combines with transcription factor CEBPB, up-regulates the expression of BCL2A1, thereby enhancing the drug resistance of HCC cells to etoposide. According to the mechanism, a screening method and kit for developing drugs for treating drug resistance of liver cancer are developed.

This application describes a novel approach to precise transcriptional control of disease-associated genes using chimeric proteins. Specifically, this disclosure provides chimeric proteins comprising a nuclear-trafficking carrier and a transcription-controlling effector, pharmaceutical composition comprising the chimeric proteins, use of the chimeric proteins and pharmaceutical compositions thereof for treatment of diseases. The novel chimeric proteins offer therapeutic potential across a broad spectrum of diseases characterized by irregularities in gene expression, especially various cancers, achieved through precise transcriptional control.

The present invention includes methods for treating a FLT3 mutated proliferative disorder comprising: measuring expression of a mutated FLT3 and a one or more driver mutations in a nuclear transport protein that results in a loss of localization of the nuclear transport protein in a sample obtained from a tumor sample obtained from the patient, wherein the presence of the one or more genetic abnormalities indicates that the patient has a poor prognosis; and administering to the patient a therapeutically effective amount of Crenolanib or a pharmaceutically acceptable salt thereof, wherein the Crenolanib increases a chance of survival of the patient having both the mutated FLT3 and mutation in NPM1 or NUP98, wherein the Crenolanib, as shown below, is administered to a subject suffering from said disorder:

The invention relates to an application of an XPO1 inhibitor in MGA function deletion type mutant tumors, in particular to an application of the XPO1 inhibitor Sanisole in preparation of a medicine for treating the MGA function deletion type mutant tumors. According to the application, the targeted therapy effect of the old medicine Selanisole on the MGA deletion type tumor is verified for the first time, ribosome biogenesis is inhibited and blocked by using nucleoplasm transport, a new use strategy of the old medicine is provided for targeted therapy, and the pan-cytotoxicity of traditional chemotherapy is avoided.

This invention discloses a dual-targeting DNA vaccine delivery system based on calcium phosphate lipid nanoparticles, belonging to the field of biomedicine. The delivery system comprises calcium phosphate containing histone H1 and an HPV E6 / E7 fusion gene plasmid, and a lipid bilayer membrane of DSPE-PEG-2000-Mannose. This system achieves targeted uptake by dendritic cells through mannose modification and relies on histone H1-mediated DNA nuclear transport. The dual targeting significantly enhances antigen expression efficiency. In vitro and in vivo experiments have demonstrated that this delivery system exhibits good biocompatibility and high stability, effectively activating antigen-specific T-cell immune responses, and possesses both HPV infection prevention and cervical cancer treatment effects, providing a new strategy for cervical cancer prevention and treatment.

A combination for use in treating cancer comprising: (a) a compound of Formula I or a pharmaceutically acceptable salt thereof, and (b) a compound of Formula II or pharmaceutically acceptable salt the

The present disclosure relates to methods of treating, preventing, and / or ameliorating a disease or disorder involving excessive Wnt signaling in a subject in need thereof, the method comprising administering to the subject an inhibitor of β-catenin nuclear transport. In certain embodiments, the disease or disorder involving excessive Wnt signaling is cancer. The present disclosure further relates to pharmaceutical compositions comprising at least one inhibitor of β-catenin nuclear transport and a pharmaceutically acceptable carrier.

The present invention relates to compounds of formula (I) or a stereoisomer or tautomer thereof, (I) wherein n, q, A1, A2, A3, A4, L1, L2, B1 and B2 have the same meaning as those defined in the claims and the description. The present application also relates to compositions, in particular medicaments, comprising such compounds, and to the use of such compounds and compositions for the prevention and / or treatment of conditions that can be treated with nuclear export protein 1 (XPO1) inhibitors, the disorders are, for example, proliferative disorders, cancer, inflammatory disorders, autoimmune disorders, viral infections, ophthalmic disorders, neurodegenerative disorders, abnormal tissue growth disorders, disorders associated with food intake, allergies, respiratory diseases, dermatological syndromes, solar injury, congestive heart failure, and hypertrophic cardiomyopathy, trauma and spinal cord injury.

The invention discloses an application of a soybean nuclear transport factor coding gene GmNTF1. The invention also discloses application of the soybean nuclear transport factor gene GmNTF1 shown in SEQ ID NO. 1 in genetic engineering modification of soybean root growth and improvement of soybean yield and mosaic virus resistance. Knockout of the gene can promote root growth and increase soybean yield, and overexpression of the gene can enhance resistance to SMV by inhibiting virus accumulation. The soybean nuclear transport factor gene GmNTF1 disclosed by the invention can be transformed into soybean by utilizing genetic engineering by constructing a gene knockout and overexpression vector, the soybean root development is promoted by knocking out the GmNTF1 gene, the soybean yield is improved, and the resistance of the soybean to soybean mosaic virus diseases can be remarkably improved by highly expressing the GmNTF1 gene.

The present invention generally relates at least in part to compositions comprising non-viral vector gene therapies that can provide a means of enhancing rate and efficiency of transport to the nucleus. Also provided herein at least in part are non-virally delivered DNA compositions that exhibit nuclear transport and can be used for the treatment of a broad range of pathologies.